The clinical signs of lupus nephritis were alleviated and the survival time was prolonged in MRL/LPR mice administered with the safe HMGB1 inhibitor ethyl pyruvate (EP) for 8 weeks (Ji et al. 2019), suggesting that EP is a potential therapeutic for SLE. The gene discussed is HMGB1; the disease is systemic lupus erythematosus.